LUMOXITI is the first and only FDA-approved CD22-directed therapy developed for the treatment of adult patients with relapsed/refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)1

Take a Targeted Approach to Hairy Cell Leukemia Treatment With LUMOXITI

LUMOXITI features PE38 fused to a recombinant murine immunoglobulin variable domain1

Recombinant murine immunoglobulin variable domain

Engineered to bind to CD22 surface antigen on CD22-expressing cells


A truncated Pseudomonas exotoxin that inhibits protein synthesis

LUMOXITI specifically targets the surface antigen CD22 which is overexpressed in hairy cells1-3

  1. CD22 is a surface antigen expressed on hairy cells
  2. LUMOXITI binds CD22 on the surface of CD22-expressing cells
  3. Once bound, LUMOXITI is internalized
  4. LUMOXITI internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death

LUMOXITI inhibits protein synthesis, resulting in apoptosis1,4

Adapted from Schneider AK et al. J Immunol Methods. 2016;435:68-76.4